Obesity is a public health problem, associated with salt sensitive hypertension, kidney inflammation, and fibrosis. N-acetyl-seryl-aspartyllysyl-proline (Ac-SDKP) is a tetra peptide with anti-inflammatory and anti-fibrotic properties. However, its effect on preventing kidney damage in obesity is unknown. We hypothesized that Zucker obese (ZO) rats on a high-salt (HS) diet develop renal damage, inflammation, fibrosis, and this is prevented with Ac-SDKP treatment.
Obesity is a public health problem, in the United States almost 70% of the population is overweight; among them, approximately 35% are obese, with a body mass index above 30 kg/m 2 . 1 Obesity is an important risk factor for end-stage renal disease due to its strong association with diabetes and hypertension. 2 The incidence of kidney damage associated to obesity has increased 10-fold in the last 15 years and is expected to rise further in the coming years. 3 Obesity is also linked to salt-sensitive hypertension in both human and animals. 4, 5 In the obese population, saltsensitive hypertension is strongly associated with the progression of target-organ damage, including end-stage renal disease. 6 The underlying mechanism of obesity-related salt sensitivity and its association with renal injury remains unclear. However, inflammation plays a key role in the development of hypertension and kidney damage associated with obesity. 7, 8 Previous studies have shown that, in obesity, renal injury is associated with glomerulosclerosis, tubule-interstitial damage, inflammation, and albuminuria. High-salt (HS) intake further aggravated these renal changes. 9 N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a tetra-peptide, naturally present in many tissues including kidney. 10 Ac-SDKP is released from its precursor thymosin β4 by 2 enzymatic steps mediated by meprin-α and prolyl oligopeptidase enzymes. 11, 12 Ac-SDKP is hydrolyzed by angiotensin-converting enzyme (ACE), and its concentration in plasma and tissue, are increased by ACE inhibitors (ACEi). 13 Studies using several experimental animal models have demonstrated that Ac-SDKP has anti-inflammatory and anti-fibrotic properties 14, 15 and that a decrease in endogenous Ac-SDKP levels promoted fibrosis in the kidney and heart. 16 Recently, we have also shown that Ac-SDKP can delay the onset of hypertension in systemic lupus erythematous. 17 However, the effect of Ac-SDKP on obesity-related kidney damage and hypertension is still unknown.
Zucker obese (ZO) rats exhibit many phenotypic traits that are common in the obesity observed in humans such us hyperinsulinemia with normoglycemia and is associated with albuminuria and a progressive decline of renal function. 18, 19 Therefore, we hypothesized that ZO rats on a HS diet develop hypertension and renal damage, and this is prevented with Ac-SDKP treatment.
METHODS

Animals
Male ZL and ZO rats at 5 weeks of age (Charles River Laboratories, Wilmington, MA) were housed in an air-conditioned room with a 12-hour light/dark cycle and received standard laboratory rat chow and tap water. Rats were allowed 7 days to acclimatize to the new environment before the experiments were performed. All surgical procedures were performed under anesthesia (50 mg/kg of sodium pentobarbital, intraperitoneal). All protocols performed in this study were approved by the Henry Ford Hospital Institutional Animal Care and Use Committee and were conducted in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
Experimental protocols
ZL and ZO rats (8 weeks old) were placed on either a normal-salt (NS; 0.4% NaCl) or HS (4% NaCl) diet (Teklad diets, Harlan, Madison, WI) and were subcutaneously infused with vehicle (0.01 N acetic acid 0.9% saline solution) or Ac-SDKP (1.6 mg/kg/day) for 8 weeks using osmotic mini-pumps (Alzet, Cupertino, CA). Each strain of rat (ZL and ZO) was divided into three groups: (i) NS infused with vehicle (NS + vehicle, n = 6); (ii) HS infused with vehicle (HS + vehicle, n = 6); and (iii) HS infused with Ac-SDKP (HS + Ac-SDKP, n = 6). Blood pressure was measured weekly with a tail-cuff method; 24-hour urine collection was carried out for urinary Ac-SDKP, albumin, and sodium excretion. At the end of the experiment, the animals were sacrificed, and tissues were weighed and collected for biochemical and histological studies.
Systolic blood pressure
Systolic blood pressure (SBP) was measured in conscious rats with a noninvasive computerized tail-cuff system (CODA, Kent Scientific, Torrington, CT), as described previously. 20 Urinary Ac-SDKP, sodium excretion, and albuminuria Animals were placed in metabolic cages for a 24-hour period for acclimatization before 24 hours urine collection. The ACEi captopril was applied to the collecting funnels and tubes at the final concentration of 10 −5 M to prevent Ac-SDKP degradation by urinary ACE. The total volume of collected urine was measured; aliquots were prepared and centrifuged twice at 4 °C and 1,200 g for 10 min (Eppendorf centrifuge 5415R). The supernatants were filtered and stored at −80 °C until further analysis. Urinary Ac-SDKP was measured using competitive enzyme linked immunosorbent assay (ELISA) kit according to the manufacturer's protocol (SPI Biolaboratories, France) as previously described. 21 Urinary albumin was determined with an ELISA kit according to the manufacturer's protocol (GenWay Biotech, San Diego, CA). The 24-hour sodium excretion values were calculated from 24-hour urine volumes and the sodium concentrations measured with a Nova Biomedical 1 electrolyte analyzer (Waltham, MA). Urine albumin excretion was calculated as the urine albumin concentration multiplied by 24-hour urine volume output.
Renal macrophage infiltration
Frozen kidney sections (6 µm) were fixed with acetone for 20 minutes. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide. Nonspecific antibody binding was blocked with 1% bovine serum albumin. Primary antibody mouse anti-rat CD68, a marker for macrophages (clone: ED-1, 1:200, Millipore), was applied, and samples were incubated overnight at 4°C. The following day, sections were incubated with biotinylated secondary horse antimouse immunoglobulin G antibodies. Immunoreactivity was detected with ABC peroxidase kit (Vectastain Elite, Vector Laboratories, Burlingame, CA) and visualized with 3-amino-9-ethylcarbazole (Zymed Laboratories, San Francisco, CA). Reddish-brown staining was considered positive. Sections were counterstained with hematoxylin to see the nucleus of the cell. Twenty consecutive regions of the section were examined at 200× magnification using a Nikon's Eclipse E600 microscope and evaluated with a computerized image analysis system (Microsuite Biological Imaging, Olympus America, Center Valley, PA). Positive cells with clearly visible nuclei were counted at high power for each section and expressed as cells per square millimeter. All histological studies have been performed with blinded analysis.
Renal fibrosis
Picrosirius red staining (PSR) was used to quantify the renal cortical and medullary interstitial collagen deposition as described previously. 14 Additionally, total collagen content of the renal cortex was determined using the hydroxyproline assay, as described previously. 22 Briefly, samples were dried and weighed, homogenized, and hydrolyzed with 6 N HCI for 16 hours at 110 °C. A standard curve of 0-5 μg of hydroxyproline was used. Data were expressed as micrograms of collagen per Abbreviations: Ac-SDKP, N-acetyl-seryl-aspartyl-lysyl-proline; GTT, glucose tolerance test; HS, high-salt; NS, normal-salt; ZL, Zucker lean; ZO, Zucker obese. *P < 0.05 (n = 6) ZO + NS vs. ZO + HS; † P < 0.05 ZO + HS vs. ZO + HS + Ac-SDKP; ǂ P < 0.05 ZL + NS vs. ZO + NS; § P < 0.05 ZL + NS vs. ZL + HS; ǁ P < 0.05 ZL + NS vs. ZL + HS + Ac-SDKP; ¶ P < 0.05 ZL + HS vs. ZL + HS + Ac-SDKP; # P < 0.05 ZO + NS vs. ZO + HS + Ac-SDKP. milligram of dry weight, assuming that collagen contains an average of 13.5% hydroxyproline.
Glomerular injury
The glomerular matrix was evaluated by periodic acidSchiff (PAS) staining (Sigma-Aldrich, SL), according to the manufacturer's protocol. A trans-mural section was taken from the upper mid-kidney section. Sequential 4 μm paraffin-embedded sections were stained with PAS. Glomeruli (30-50) within the 20 consecutive fields of the renal cortex were photographed at 200× magnification. The dark purple color within the glomeruli was considered a positive signal representing the extracellular matrix. The degree of glomerulosclerosis was determined as a percentage of the glomerular tuft area using Microsuite Biological Imaging Software.
Intraperitoneal glucose tolerance test (ipGTT)
On week 8 of the treatment, rats were fasted overnight, blood samples were taken from the tail vein, and glucose was measured using a glucometer (Bayer Contour Blood glucose meter) at 0 (fasting), 15, 30, 60, 90, and 120 minutes after giving an intraperitoneal injection of glucose (2 g/kg). The total area under the curve (AUC) for glucose during the ipGTT (2-hour glucose area under curve) was calculated using the Graph pad Prism software version 5.01.
Statistical analysis. A nonparametric two-sample
Wilcoxon test was used to compare contrasts of interest in all the data. To adjust for multiple testing, Hochberg's method was used to determine the significance. The adjustment was made on groups of similar tests. A P value less than 0.05 were considered evidence of significant differences.
RESULTS
Body weight and urinary Ac-SDKP
ZO rats showed a significantly higher body weight than ZL rats (Table 1) . Neither HS diet nor Ac-SDKP treatment showed any effect on body weight in ZL or ZO rats. Compared to ZL rats, ZO rats showed significant glucose intolerance (Table 1) . We observed that the high-salt diet further increased the glucose intolerance in ZO rats, but it had no effect on ZL rats. Ac-SDKP treatment showed no effect on glucose intolerance. As we expected, 24-hour urinary Ac-SDKP excretion was significantly higher (10-to 20-fold) in ZL and ZO rats receiving Ac-SDKP treatment than in the vehicle-treated groups. No effects of high salt were observed in Ac-SDKP excretion. Upon high salt diet, ZO rats have significantly higher urine volume compared to ZL rats but Ac-SDKP treatment did not affect it.
Renal inflammation
Macrophage infiltration was examined by immunohistochemistry. Compared to ZL rats, ZO rats showed increased numbers of CD68+ positive cells (macrophages) infiltrating the renal parenchyma (Figure 1 ). The HS diet significantly increased the number of infiltrating macrophages in both ZL and ZO rats, but this increase was markedly higher in ZO rats fed HS. Ac-SDKP treatment significantly decreased the infiltrating renal macrophages in ZO rats but not in ZL rats. These data indicated that HS diet exaggerated the renal inflammation, markedly in obese animals, and that is prevented by Ac-SDKP treatment.
Renal fibrosis
Both the cortical and medullary interstitial fibrosis quantified by PSR staining was similar in ZL and ZO rats fed a normal diet at 16 weeks of age (Figure 2 ). HS diet in ZO rats showed a significant increase in the cortical and medullary interstitial fibrosis compared to ZL rats and Ac-SDKP treatment attenuated this increase. In addition, analysis of total renal collagen content by a hydroxyproline assay confirmed our finding that a HS diet significantly increased the total renal collagen content in both ZL and ZO rats, which was significantly decreased by Ac-SDKP treatment (Table 1) .
Glomerular damage
The effect of Ac-SDKP on glomerulosclerosis was assessed by Periodic Acid-Schiff staining (PAS). Compared to ZL rats, ZO rats exhibited markedly glomerulosclerosis on NS diet (Figure 3) . HS diet for 8 weeks showed a significant increase in glomerulosclerosis in ZO rats but not in ZL rats, and this increase was significantly attenuated by treatment with Ac-SDKP in ZO rats (Figure 3) .
Albuminuria, which is a marker of glomerular damage, was significantly higher in ZO rats compared to ZL rats at 16 weeks of age (Table 1) . Interestingly, there was a trend that HS increased albuminuria in ZO rats and Ac-SDKP treatment decreased it but it did not reach the statistical significance. 
Systolic blood pressure
At baseline, no difference was found in SBPs of ZL and ZO rats (Mean ± SD: 127.5 ± 21.85 and 107.8 ± 15.20 mm Hg; P = 0.11) (Figure 4 ). ZO rats started showing a significant increase in SBP from week 2 of the HS diet (10 weeks of age), and it continued to increase until week 8 (16 weeks of age). In contrast, ZL rats did not show any increase in SBP with the HS diet intake. Ac-SDKP treatment did attenuate the increased blood pressure in ZO rats fed a HS diet, but it did not show any effect on blood pressure in ZL rats. In the last week of the protocol, Ac-SDKP still decreased the blood pressure in ZO rats, but the difference with rats receiving HS was not statistically significant.
As we expected, the quantification of sodium excretion shows that a HS diet increases sodium excretion in both ZL and ZO rats and that Ac-SDKP treatment did not affect it, indicating that there was no difference in salt intake in these groups of animals upon Ac-SDKP treatment (Table 1) .
DISCUSSION
In the current study, we examined the protective effects of Ac-SDKP on HS-induced kidney damage in obesity. Our results showed that HS diet aggravates renal damage in ZO rats, inducing renal macrophage infiltration, interstitial fibrosis, glomerulosclerosis along with hypertension and that Ac-SDKP prevented all these effects. Additionally, Ac-SDKP reduced both renal cortical and medullary fibrosis but failed to have any beneficial effect on albuminuria. These findings point out the participation of inflammation in the obesity induced salt sensitivity and renal damage. Thus, Ac-SDKP or its analog, resistant to enzymatic degradation, could be used as a novel and specific therapeutic strategy for renal damage in obesity.
Obese individuals are predisposed to develop salt sensitive hypertension and renal damage. In obesity, the kidneys initially become inflamed and eventually develop fibrosis; this effect is further aggravated with HS intake. Ac-SDKP is a naturally occurring tetra-peptide that has anti-inflammatory and anti-fibrotic properties in several models of cardiovascular and renal diseases 14, 23 but its effect on obesity-related kidney damage are currently unknown. Many studies have provided the evidence that infiltrating macrophages play a vital role in mediating obesity related kidney damage. 24, 25 Our data indicated macrophage infiltration was markedly increased in the kidney of ZO rats compared to the ZL rats at 16 weeks of age, similar to previous studies. 26, 27 HS diet further exaggerated macrophage infiltration in both ZL and ZO rats. This is in line with other studies, wherein HS intake induced macrophage infiltration. 14, 28 Macrophages infiltration leads to the release of proinflammatory cytokines and chemokines like tumor necrosis factor α, Interleukin (IL)-6, IL-1β, Monocyte attractant protein (MCP)-1. 29 We report here that Ac-SDKP treatment significantly reduced macrophage infiltration in ZL and ZO rats fed on HS. The beneficial effect exerted by Ac-SDKP on the reduction of macrophage infiltration in ZO rats is similar to our previously reported study, wherein Ac-SDKP prevented macrophage infiltration in both the Dahl salt-sensitive and resistant rats fed a HS diet. 14 Generally renal fibrosis is the end result of inflammation, and the same is evident in our current study. Renal fibrosis (total renal collagen content) was increased in both ZL and ZO rats fed a HS diet, and Ac-SDKP treatment prevented this increase. Several mechanisms may be mediating the anti-fibrotic effects of Ac-SDKP. Along with the anti-inflammatory effects, It is known that Ac-SDKP decreases transforming growth factorbeta/Smad signaling, which could be the underlying mechanisms associated with the decreased fibrosis. 23 Interestingly, we also noticed increased total renal collagen content in HS-fed ZL rats, indicating high salt, independent of obesity and hypertension per se, can exert mild renal damage. In ZO rats, increases in the glomerulosclerosis are attributed to the high glomerular capillary pressure followed by the infiltration of immune cells. 27, 30 In our study, glomerulosclerosis was also significantly increased in the ZO rats, and it was further aggravated by a HS diet. Since Ac-SDKP has been shown to reduce glomerulosclerosis in numerous studies, including db/db mice and Dahl salt-sensitive rats, 14, 31 we investigated whether Ac-SDKP reduced glomerulosclerosis in ZO rats and found that indeed Ac-SDKP treatment significantly reduced glomerulosclerosis in ZO rats.
Parallel to glomerulosclerosis, ZO rats also develop albuminuria, but the HS diet did not worsen it in either ZO rats or lean controls. Although Ac-SDKP treatment decreased glomerulosclerosis, it failed to ameliorate albuminuria in the ZO rats. Ac-SDKP treatment has been shown to decrease albuminuria in several models of renal diseases, such as Dahl salt-sensitive rats, 5/6 nephrectomy, and deoxycorticosterone acetate-salt induced hypertension. 14, 15, 20 ZO rats are obese, hyperinsulinemic, and glucose-intolerant, thus, the mechanism of albuminuria in this animal model could be different from that observed in previously reported models. Additionally, recent findings have suggested that urinary albumin excretion could result either because of the defect in the glomerular filtration barrier and/or defect in the albumin absorption in the proximal tubule. 32, 33 Since Ac-SDKP treatment improved the glomerular damage observed in ZO rats but did not ameliorate albuminuria, one can speculate that part of the albuminuria observed in ZO rats may be due to a defect in proximal tubule reabsorption. In line with our present finding, Ac-SDKP did not reduce albuminuria in db/ db mice, a mouse model of hyperinsulinemic diabetes with obesity. 31 However, a separate study is required to understand the mechanism of albuminuria in these ZO rats.
We also showed that a HS diet increases the SBP only in ZO rats but not in ZL rats, confirming previous reports that ZO rats are salt sensitive. 4, 34 We found that SBP was significantly increased in the ZO rats after 2 weeks of HS and that it remained elevated until the end of the 8 weeks of treatment compared to the ZO rats fed a NS diet. Ac-SDKP treatment significantly reduced systolic blood pressure in the HS-fed ZO rats. In general, Ac-SDKP does not have any beneficial effect in lowering the blood pressure in various models of hypertension. 14, 15, 20 However, recently, we have reported that Ac-SDKP delayed the onset of hypertension in an autoimmune model of systemic lupus erythematous. 17 It is known that inflammation plays a role in blood pressure in various hypertension models, 35, 36 and decreasing the inflammation reduces the elevated blood pressure. 35, 37 Thus, in our study, the reduction in renal inflammation induced by Ac-SDKP could be a possible explanation for the decreased blood pressure in the HS-fed ZO rats.
We did not observe any change in the 24-hour sodium excretion in HS-fed ZL rats or HS-fed ZO rats with Ac-SDKP treatment. This observation eliminates the potential role of the lower sodium intake in Ac-SDKP-treated animals. At 8th week on HS, the blood pressure still tended to be lower in Ac-SDKP-treated ZO rats than in ZO rats without Ac-SDKP treatment; however, this decrement failed to reach statistical significance. In summary, our study provides evidence that a HS diet increased the renal damage (macrophages infiltration, fibrosis, and glomerulosclerosis) and blood pressure in ZO rats and that Ac-SDKP treatment prevented these changes without reducing albuminuria. Additionally, a HS diet per se was sufficient to exert mild renal inflammation in ZL rats. The HS diet increased glucose intolerance in ZO rats but the mechanism involved in this observation is not clear, however, studies from other labs have also shown similar findings. 38, 39 On the contrary, Ac-SDKP treatment did not show any effect on glucose intolerance.
We conclude that in HS-fed ZO rats, Ac-SDKP reduced renal inflammation and fibrosis and prevented/delayed the onset of hypertension.
